{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:55:40Z","timestamp":1793404540891,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Whether newer P2Y<jats:sub>12<\/jats:sub> inhibitors are more efficacious and safer than clopidogrel and whether there is a superior one remain uncertain. We compared the effect of P2Y<jats:sub>12<\/jats:sub> inhibitors on clinical outcomes in patients with acute coronary syndrome (ACS). Randomized controlled trials comparing clopidogrel, prasugrel, ticagrelor, or cangrelor, in combination with aspirin were searched. Sixteen trials with altogether 77,896 patients were included. Compared to clopidogrel, cardiovascular mortality was reduced with prasugrel (OR 0.85, 95% CI 0.75\u20130.97) and ticagrelor (0.82, 0.73\u20130.93). Myocardial infarction (0.75, 0.63\u20130.89) and major adverse cardiovascular events (0.80, 0.69\u20130.94) were reduced by prasugrel. Stent thrombosis was reduced by prasugrel (0.49, 0.38\u20130.63), ticagrelor (0.72, 0.57\u20130.90), and cangrelor (0.59, 0.43\u20130.81). It was reduced more by prasugrel than ticagrelor (0.69, 0.51\u20130.93). There were more major bleeds with prasugrel (1.24, 1.05\u20131.48). Thrombolysis in Myocardial Infarction (TIMI) major bleeding was increased with prasugrel compared to clopidogrel (1.36, 1.11\u20131.66) and ticagrelor (1.33, 1.06\u20131.67). TIMI minor bleeding was increased with prasugrel (1.44, 1.16\u20131.77) and cangrelor (1.47, 1.01\u20132.16) compared to clopidogrel while it was increased with prasugrel compared to ticagrelor (1.32, 1.01\u20131.72). Prasugrel is preferable to those ACS patients at low bleeding risk to reduce cardiovascular events whereas ticagrelor is a relatively safe antiplatelet drug of choice for most patients.<\/jats:p>","DOI":"10.1038\/s41598-020-73871-x","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T10:03:22Z","timestamp":1602151402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and safety of newer P2Y12 inhibitors for acute coronary syndrome: a network meta-analysis"],"prefix":"10.1038","volume":"10","author":[{"given":"Yue","family":"Fei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheuk Kiu","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard Man Yung","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"issue":"24","key":"73871_CR1","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","volume":"64","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam, E. A. et al. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 64(24), e139\u2013e228 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"73871_CR2","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","volume":"127","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara, P. T. et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation 127(4), e362-425 (2013).","journal-title":"Circulation"},{"key":"73871_CR3","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf, S. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494\u2013502 (2001).","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"73871_CR4","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","volume":"107","author":"PA Gurbel","year":"2003","unstructured":"Gurbel, P. A., Bliden, K. P., Hiatt, B. L. & O\u2019Connor, C. M. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107(23), 2908\u20132913 (2003).","journal-title":"Circulation"},{"issue":"14","key":"73871_CR5","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","volume":"49","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo, D. J. et al. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49(14), 1505\u20131516 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"20","key":"73871_CR6","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001\u20132015 (2007).","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"73871_CR7","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","volume":"56","author":"RF Storey","year":"2010","unstructured":"Storey, R. F. et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J. Am. Coll. Cardiol. 56(18), 1456\u20131462 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"73871_CR8","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045\u20131057 (2009).","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"73871_CR9","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","volume":"30","author":"L Wallentin","year":"2009","unstructured":"Wallentin, L. P2Y(12) inhibitors: Differences in properties and mechanisms of action and potential consequences for clinical use. Eur. Heart. J. 30(16), 1964\u20131977 (2009).","journal-title":"Eur. Heart. J."},{"issue":"24","key":"73871_CR10","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","volume":"361","author":"RA Harrington","year":"2009","unstructured":"Harrington, R. A. et al. Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med. 361(24), 2318\u20132329 (2009).","journal-title":"N. Engl. J. Med."},{"key":"73871_CR11","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","volume":"361","author":"DL Bhatt","year":"2009","unstructured":"Bhatt, D. L. et al. Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med. 361, 2330\u20132341 (2009).","journal-title":"N. Engl. J. Med."},{"key":"73871_CR12","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMe0910677","volume":"361","author":"A Kastrati","year":"2009","unstructured":"Kastrati, A. & Ndrepepa, G. Cangrelor\u2014A champion lost in translation?. N. Engl. J. Med. 361, 2382\u20132384 (2009).","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"73871_CR13","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","volume":"368","author":"DL Bhatt","year":"2013","unstructured":"Bhatt, D. L. et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N. Engl. J. Med. 368(14), 1303\u20131313 (2013).","journal-title":"N. Engl. J. Med."},{"key":"73871_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijcard.2017.10.006","volume":"250","author":"A Eisen","year":"2018","unstructured":"Eisen, A. et al. Cangrelor compared with clopidogrel in patients with prior myocardial infarction\u2014Insights from the CHAMPION trials. Int. J. Cardiol. 250, 49\u201355 (2018).","journal-title":"Int. J. Cardiol."},{"issue":"19","key":"73871_CR15","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca, M. P. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 372(19), 1791\u20131800 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"73871_CR16","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"GN Levine","year":"2016","unstructured":"Levine, G. N. et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA guideline for coronary artery bypass graft surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation 134(10), e123\u2013e155 (2016).","journal-title":"Circulation"},{"issue":"3","key":"73871_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli, M. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart. J. 39(3), 213\u2013260 (2018).","journal-title":"Eur. Heart. J."},{"issue":"4","key":"73871_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jacc.2017.11.008","volume":"71","author":"Z Motovska","year":"2018","unstructured":"Motovska, Z. et al. 1-year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor. J. Am. Coll. Cardiol. 71(4), 371\u2013381 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"16","key":"73871_CR19","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","volume":"381","author":"S Sch\u00fcpke","year":"2019","unstructured":"Sch\u00fcpke, S. et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N. Engl. J. Med. 381(16), 1524\u20131534 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"73871_CR20","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran, R. et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. Circulation 123(23), 2736\u20132747 (2011).","journal-title":"Circulation"},{"issue":"4","key":"73871_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jrsm.1058","volume":"3","author":"G Rucker","year":"2012","unstructured":"Rucker, G. Network meta-analysis, electrical networks and graph theory. Res. Synth. Methods. 3(4), 312\u2013324 (2012).","journal-title":"Res. Synth. Methods."},{"key":"73871_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/0962280207080643","volume":"17","author":"G Salanti","year":"2008","unstructured":"Salanti, G., Higgins, J. P., Ades, A. E. & Ioannidis, J. P. Evaluation of networks of randomized trials. Stat. Methods. Med. Res. 17, 279\u2013301 (2008).","journal-title":"Stat. Methods. Med. Res."},{"issue":"19","key":"73871_CR23","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","volume":"50","author":"CP Cannon","year":"2007","unstructured":"Cannon, C. P. et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial. J. Am. Coll. Cardiol. 50(19), 1844\u20131851 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"73871_CR24","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1253\/circj.CJ-15-0112","volume":"79","author":"S Goto","year":"2015","unstructured":"Goto, S., Huang, C. H., Park, S. J., Emanuelsson, H. & Kimura, T. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome\u2014Randomized, double-blind, phase III PHILO study. Circ. J. 79(11), 2452\u20132460 (2015).","journal-title":"Circ. J."},{"issue":"2","key":"73871_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/FJC.0000000000000390","volume":"68","author":"X Tang","year":"2016","unstructured":"Tang, X. et al. Assessment of ticagrelor versus clopidogrel treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. J. Cardiovasc. Pharmacol. 68(2), 115\u2013120 (2016).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"73871_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ahj.2017.07.013","volume":"192","author":"P Dehghani","year":"2017","unstructured":"Dehghani, P. et al. Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI. Am. Heart. J. 192, 105\u2013112 (2017).","journal-title":"Am. Heart. J."},{"key":"73871_CR27","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.2147\/TCRM.S108965","volume":"12","author":"H Wang","year":"2016","unstructured":"Wang, H. & Wang, X. Efficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndrome. Ther. Clin. Risk. Manag. 12, 1101\u20131105 (2016).","journal-title":"Ther. Clin. Risk. Manag."},{"issue":"5","key":"73871_CR28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jamacardio.2018.0612","volume":"3","author":"O Berwanger","year":"2018","unstructured":"Berwanger, O. et al. Ticagrelor vs clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: A randomized clinical trial. JAMA. Cardiol. 3(5), 391\u2013399 (2018).","journal-title":"JAMA. Cardiol."},{"issue":"25","key":"73871_CR29","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1161\/CIRCULATIONAHA.104.502815","volume":"111","author":"SD Wiviott","year":"2005","unstructured":"Wiviott, S. D. et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111(25), 3366\u20133373 (2005).","journal-title":"Circulation"},{"issue":"14","key":"73871_CR30","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","volume":"367","author":"MT Roe","year":"2012","unstructured":"Roe, M. T. et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N. Engl. J. Med. 367(14), 1297\u20131309 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"73871_CR31","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1253\/circj.CJ-13-1482","volume":"78","author":"S Saito","year":"2014","unstructured":"Saito, S. et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. Circ. J. 78(7), 1684\u20131692 (2014).","journal-title":"Circ. J."},{"issue":"7","key":"73871_CR32","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3109\/09537104.2013.845874","volume":"25","author":"NP Dridi","year":"2014","unstructured":"Dridi, N. P. et al. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response\u2013the TAILOR (Thrombocytes AndIndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial. Platelets 25(7), 506\u2013512 (2014).","journal-title":"Platelets"},{"issue":"8","key":"73871_CR33","first-page":"13310","volume":"8","author":"R Xiong","year":"2015","unstructured":"Xiong, R. et al. A randomized controlled trial to assess the efficacy and safety of doubling dose clopidogrel versus ticagrelor for the treatment of acute coronary syndrome in patients with CYP2C19*2 homozygotes. Int. J. Clin. Exp. Med. 8(8), 13310\u201313316 (2015).","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"14","key":"73871_CR34","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","volume":"381","author":"PG Steg","year":"2019","unstructured":"Steg, P. G. et al. Ticagrelor in patients with stable coronary disease and diabetes. N. Engl. J. Med. 381(14), 1309\u20131320 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"73871_CR35","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.amjcard.2015.05.058","volume":"116","author":"C Bavishi","year":"2015","unstructured":"Bavishi, C., Panwar, S., Messerli, F. H. & Bangalore, S. Meta-Analysis of comparison of the newer oral P2Y12 inhibitors (prasugrel or ticagrelor) to clopidogrel in patients with non-ST-elevation acute coronary syndrome. Am. J. Cardiol. 116(5), 809\u2013817 (2015).","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"73871_CR36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/FJC.0000000000000451","volume":"69","author":"L Zhang","year":"2017","unstructured":"Zhang, L. et al. Meta-analysis of comparison of the newer P2Y12 inhibitors (oral preparation or intravenous) to clopidogrel in patients with acute coronary syndrome. J. Cardiovasc. Pharmacol. 69(3), 147\u2013155 (2017).","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"19","key":"73871_CR37","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jacc.2010.07.012","volume":"56","author":"A Bellemain-Appaix","year":"2010","unstructured":"Bellemain-Appaix, A. et al. New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: A meta-analysis. J. Am. Coll. Cardiol. 56(19), 1542\u20131551 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"73871_CR38","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.atherosclerosis.2014.01.017","volume":"233","author":"XF Tang","year":"2014","unstructured":"Tang, X. F. et al. Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: A meta-analysis of randomized trials. Atherosclerosis. 233(2), 568\u2013578 (2014).","journal-title":"Atherosclerosis."},{"issue":"1","key":"73871_CR39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1160\/TH12-06-0377","volume":"109","author":"D Aradi","year":"2013","unstructured":"Aradi, D., Kom\u00f3csi, A., Vorobcsuk, A. & Serebruany, V. L. Impact of clopidogrel and potent P2Y 12-inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A systematic review and meta-analysis. Thromb. Haemost. 109(1), 93\u2013101 (2013).","journal-title":"Thromb. Haemost."},{"issue":"11","key":"73871_CR40","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.amjcard.2017.03.011","volume":"119","author":"R Shah","year":"2017","unstructured":"Shah, R. et al. Meta-analysis of the relative efficacy and safety of oral P2Y12 inhibitors in patients with acute coronary syndrome. Am. J. Cardiol. 119(11), 1723\u20131728 (2017).","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"73871_CR41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11239-012-0838-z","volume":"36","author":"S Chatterjee","year":"2013","unstructured":"Chatterjee, S. et al. Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. J. Thromb. Thrombolysis. 36(3), 223\u2013232 (2013).","journal-title":"J. Thromb. Thrombolysis."},{"issue":"10","key":"73871_CR42","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jcin.2016.02.013","volume":"9","author":"AM Rafique","year":"2016","unstructured":"Rafique, A. M. et al. Optimal P2Y12 inhibitor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A network meta-analysis. JACC.Cardiovasc. Interv. 9(10), 1036\u20131046 (2016).","journal-title":"JACC.Cardiovasc. Interv."},{"issue":"9665","key":"73871_CR43","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","volume":"373","author":"G Montalescot","year":"2009","unstructured":"Montalescot, G. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomized controlled trial. Lancet 373(9665), 723\u2013731 (2009).","journal-title":"Lancet"},{"issue":"9","key":"73871_CR44","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.amjcard.2014.02.002","volume":"113","author":"SJ Brener","year":"2014","unstructured":"Brener, S. J. et al. Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial). Am. J. Cardiol. 113(9), 1457\u20131460 (2014).","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"73871_CR45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.acvd.2015.08.005","volume":"109","author":"R Bacquelin","year":"2016","unstructured":"Bacquelin, R. et al. Safety of prasugrel in real- world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study). Arch. Cardiovasc. Dis. 109(1), 31\u201338 (2016).","journal-title":"Arch. Cardiovasc. Dis."},{"issue":"5","key":"73871_CR46","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.acvd.2016.01.009","volume":"109","author":"B Lattuca","year":"2016","unstructured":"Lattuca, B. et al. One-year incidence and clinical impact of bleeding events in patients treated with prasugrel or clopidogrel after ST-segment elevation myocardial infarction. Arch. Cardiovasc. Dis. 109(5), 337\u2013347 (2016).","journal-title":"Arch. Cardiovasc. Dis."},{"key":"73871_CR47","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S0140-6736(20)30325-1","volume":"395","author":"M Gimbel","year":"2020","unstructured":"Gimbel, M. et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): The randomized, open-label, non-inferiority trial. Lancet 395, 1374\u20131381 (2020).","journal-title":"Lancet"},{"issue":"9909","key":"73871_CR48","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","volume":"382","author":"PG Steg","year":"2013","unstructured":"Steg, P. G. et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data. Lancet 382(9909), 1981\u20131992 (2013).","journal-title":"Lancet"},{"issue":"5","key":"73871_CR49","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ahj.2012.02.018","volume":"163","author":"S Leonardi","year":"2012","unstructured":"Leonardi, S. et al. Rationale and design of the cangrelor versus standard therapy to achieve optimal management of platelet Inhibition PHOENIX trial. Am. Heart. J. 163(5), 768-776.e2 (2012).","journal-title":"Am. Heart. J."},{"key":"73871_CR50","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.ijcard.2016.06.070","volume":"220","author":"Y Fei","year":"2016","unstructured":"Fei, Y., Tsoi, M. F., Cheung, T. T. & Cheung, B. M. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of randomized controlled trials. Int. J. Cardiol. 220, 895\u2013900 (2016).","journal-title":"Int. J. Cardiol."},{"key":"73871_CR51","doi-asserted-by":"publisher","first-page":"8703627","DOI":"10.1155\/2020\/8703627","volume":"2020","author":"G Patti","year":"2020","unstructured":"Patti, G., Micieli, G., Cimminiello, C. & Bolognese, L. The role of clopidogrel in 2020: A reappraisal. Cardiovasc. Ther. 2020, 8703627 (2020).","journal-title":"Cardiovasc. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73871-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73871-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73871-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T20:27:56Z","timestamp":1670358476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73871-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["73871"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-73871-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,8]]},"assertion":[{"value":"25 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16794"}}